a Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel and University of Basel, Basel, Switzerland
b Institute for Infectious Diseases, University of Bern, Bern, Switzerland
c Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
d University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
e Center for Internal Medicine, Hirslanden Klinik Aarau, Aarau, Switzerland
f Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
g Infectious Diseases Service, Department of Medicine, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland
h Department of Cardiology, University Hospital Basel and University of Basel, Basel, Switzerland
i Cardiology Unit, Hospital Emmental, Langnau, Switzerland
j Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
k Pediatric Cardiology, Department of Surgery, Pediatric Heart Center, University Children's Hospital, Zurich, Switzerland
After considerable revision of the previous guidelines on infective endocarditis prophylaxis by the American Heart Association in 2007, the Swiss recommendations were revised and published accordingly in 2008 . The Swiss societies of Infectious Diseases (SSI), Pediatric Cardiology and Cardiology and the Pediatric Infectious Disease Group of Switzerland present the current update in a joint initiative. The summary is freely available on the web (https://ssi.guidelines.ch/ → infective endocarditis/prevention).
What is new compared to the 2008 recommendations?
The herein presented endocarditis prophylaxis recommendations differ only in minor points from those published in 2008. Antibiotic prophylaxis is no longer recommended for patients with unrepaired ventricular septal defects and patent ductus arteriosus, in accordance with the guidelines of the European Society of Cardiology (2015) . Antibiotic prophylaxis is recommended only for individuals at high risk. This recommendation has been valid in Switzerland since 2008 and continues to be so. Within this high-risk group there is a ranking order, and the conditions are presented accordingly.
Population at high risk for infective endocarditis
- Patients with a previous episode of infective endocarditis.
- Patients with any prosthetic valve (biological or mechanical), including a transcatheter valve (transcatheter valve implantation), or those in whom any prosthetic material was used for cardiac valve repair.
- Patients with congenital heart disease (CHD).
- Any type of cyanotic CHD (i.e., unrepaired CHD).
- Any type of CHD repaired with prosthetic material, whether placed surgically or by percutaneous techniques.⇒ At risk up to 6 months after the procedure.
- Any type of CHD repaired with prosthetic material, whether placed surgically or by percutaneous techniques.⇒ At risk for life if residual shunt persists or if residual finding persists after the procedure (for example incomplete tissue ingrowth of prosthetic material).
- There is no evidence to recommend antimicrobial prophylaxis for cardiac transplant recipients who develop cardiac valvulopathy. The indication should be discussed on a case-by-case basis. The patient should contact their transplant specialist to evaluate the indication prior to an elective intervention.
Dental and non-dental interventions
Recommendations for antibiotic prophylaxis for the prevention of infective endocarditis focus mainly on dental interventions. Recommendations for antibiotic prophylaxis for other interventions, such as ear-nose-throat surgery, skin surgery or interventions within the respiratory tract, gastrointestinal tract or urogenital tract, are not part of these specific recommendations for antibiotic endocarditis prophylaxis. Detailed recommendations for peri-interventional and perioperative antibiotic prophylaxis for non-dental procedures have been published by Swissnoso . These recommendations apply to all patients, including those with elevated risk for infective endocarditis. A few exceptions for patients at high risk of endocarditis are published as part of these recommendations on the SSI website (https://ssi.guidelines.ch/ → infective endocarditis/prevention and list below). These include, for example, antibiotic treatment when an incision of a skin abscess is performed and the choice of antimicrobial agents for abdominal surgery (i.e., amoxicillin/clavulanic acid instead of cefuroxime or cefazolin to cover activity against Enterococcus spp.). Recommendations on the new endocarditis card (similar to an allergy passport that is carried by the patients) are limited to dental interventions. For non-dental interventions, we refer to the published recommendations of the different societies [3, 4] and of the SSI (list below and https://ssi.guidelines.ch/ → infective endocarditis/prevention).
Antibiotic prophylaxis is not recommended for local anesthetic injections in non-infected tissues, treatment of superficial caries, removal of sutures, dental X-rays, placement or adjustment of removable prosthodontic or orthodontic appliances or braces, following the shedding of deciduous teeth, or superficial trauma to the lips and oral mucosa.
Antibiotic prophylaxis should only be administered for dental procedures with a tendency to bleed, namely those involving:
- manipulation of the gingival or periapical region of the teeth;
- perforation of the oral mucosa.
Antibiotic prophylaxis prior to dental intervention and dental hygiene*
It is recommended to take the antibiotic prophylaxis one hour prior to the intervention:
- Adults: 2 g orally (p.o.)
- Children: 50 mg/kg (maximum dose 2 g) p.o.
Alternatives in case of penicillin allergy
- Adults: cefuroxime axetil 1 g p.o. in patients with delayed hypersensitivity reaction
- Children: cefuroxime axetil 50 mg/kg p.o. (maximum dose 1 g) in patients with delayed hypersensitivity reaction
- Adults: clindamycin 600 mg p.o. in patients with immediate hypersensitivity reaction
- Children: clindamycin 20 mg/kg p.o. (maximum dose 600 mg) in patients with immediate hypersensitivity reaction
In case of inability to swallow the antibiotic pill
- Adults: amoxicillin 2 g intravenously (i.v.)
- Children: amoxicillin 50 mg/kg i.v. (maximum dose 2 g)
Alternatives in case of penicillin allergy and inability to swallow the antibiotic pill
- Adults: cefazolin 1 g i.v. or ceftriaxone 2 g i.v. in patients with delayed hypersensitivity reaction
- Children: cefazolin 25 mg/kg i.v. (maximum dose 1 g) or ceftriaxone 50 mg/kg i.v. (maximum dose 2 g) in patients with delayed hypersensitivity reaction
- Adults: clindamycin 600 mg i.v. or vancomycin 1 g i.v. in patients with immediate hypersensitivity reaction
- Children: clindamycin 20 mg/kg i.v. (maximum dose 600 mg) or vancomycin 20 mg/kg i.v. (maximum dose 1 g) in patients with immediate hypersensitivity reaction
* There will be a separate endocarditis card for adults and children
- Perioperative antimicrobial prophylaxis is not recommended for tonsillectomy in patients not at risk for infective endocarditis. There is no evidence-based recommendation for perioperative antimicrobial prophylaxis in patients with risk for infective endocarditis.
- Tonsillectomy is associated with bacteremia in a considerable proportion of patients undergoing this procedure. There is no evidence that perioperative antimicrobial prophylaxis prevents infective endocarditis in patients at risk. The majority of the expert group favor perioperative antimicrobial prophylaxis for tonsillectomy in patients at risk for infective endocarditis. The agent should contain activity against microorganisms belonging to the oral microbiom.
- The expert group clearly categorizes this statement as an expression of opinion and not as a guideline recommendation. The expert group states also that the number of opinions does not correlate with the level of evidence.
Respiratory tract procedures
- Antibiotic prophylaxis is not recommended for bronchoscopy, laryngoscopy, or transnasal or endotracheal intubation.
- For invasive procedures to treat an established infection (i.e., drainage of abscesses), an empiric antibiotic regimen containing anti-staphylococcal activity (S. aureus) should be used.
- Antibiotic prophylaxis is not recommended for gastroscopy, colonoscopy, low risk laparoscopic biliary tract procedures (see also the 2015 recommendations for perioperative antimicrobial prophylaxis of Swissnoso), cystoscopy, vaginal or caesarean delivery, or transesophageal echocardiography.
- In the case of an established infection, an empiric antibiotic regimen containing anti-enterococcal activity should be used.
- If antibiotic therapy is indicated to prevent wound infection or sepsis associated with a gastrointestinal or genitourinary tract procedure, perioperative or peri-interventional antimicrobial prophylaxis containing anti-enterococcal activity should be used (see table 1, dose recommendations are based on normal renal and liver function).
|Table 1: Perioperative or peri-interventional antimicrobial prophylaxis for gastrointestinal/genitourinary procedures.|
|Perioperative antimicrobial prophylaxis||No allergy to penicillin||Allergy to penicillin|
|AdultsSingle dose 30 – 60 minutes before procedure||Amoxicillin/clavulanate 2.2 g i.v.||Vancomycin 1 g i.v.plus gentamicin* 3 mg/kg i.v.(or ciprofloxacin 400 mg i.v.)plus metronidazole 500 mg i.v.|
|ChildrenSingle dose 30 – 60 min before procedure||Amoxicillin/clavulanate 50 mg/kg i.v. (maximum 2.2 g i.v.)||Vancomycin 20 mg/kg i.v. (maximum 1 g i.v.)plus gentamicin 2.5 mg/kg (maximum 80 mg) i.v.plus metronidazole 10 mg/kg i.v. (maximum 500 mg i.v.)|
|*Alternative to gentamicin; another aminoglycoside (e.g., amikacin) can be administered. Kindly contact your institutional infectious diseases physician.|
Skin and soft tissue procedures
- Antibiotic prophylaxis is not recommended for any procedure.
- For surgical procedures on infected skin/skin structure (e.g., incision of skin abscess): an empiric antibiotic regimen should contain an agent with activity against staphylococci and beta-hemolytic streptococci.
Cardiac or vascular interventions
- Preoperative screening for nasal carriage of Staphylococcus aureus is recommended before elective cardiac surgery in order to treat carriers.
- Local treatment without screening for S. aureus is not recommended.
- Potential sources of infection (e.g., dental foci) should be treated/removed ≥2 weeks prior to the intervention.
- Perioperative antibiotic prophylaxis is recommended before placement of a pacemaker or implantable cardioverter defibrillator.
- Perioperative antibiotic prophylaxis should be administered in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic or other foreign material (for example graft implantation for endovascular aneurysm repair).
- Prophylaxis should be started immediately before the procedure and repeated if the procedure is prolonged. Prophylaxis should not be prolonged for longer than 48 hours.
Areas of uncertainty
There is no scientific evidence to support a recommendation for or against antibiotic prophylaxis in cardiac transplant patients who develop valvulopathy. The majority of members of the expert group do not recommend antibiotic prophylaxis for this patient group. At the same time, the expert group states that it is not meaningful to express a generalizable recommendation for a patient population that is relatively small with (different) complex disease histories in Switzerland. Because all heart transplant patients are followed in specialized institutions, it is within the responsibility of the treating transplant physician to prescribe antibiotic prophylaxis prior to the intervention following a case-by-case evaluation.
Bacteremia occurs frequently during tonsillectomy [5-8]. However, perioperative antibiotic prophylaxis is not recommended for tonsillectomy in patients not at risk for developing infective endocarditis [3, 9]. The majority of the expert group favor the administration of antimicrobial prophylaxis in high-risk patients undergoing tonsillectomy [1, 8, 10]. The antimicrobial agent must have activity against organisms belonging to the oral microbiome (e.g., amoxicillin/clavulanic acid, 2.2 g in adults and 50 mg/kg [maximum dose 2.2 g] in children, given intravenously 30 minutes prior to incision). However, due to a lack of evidence, the expert group clearly categorizes this statement as expert opinion and not as a guideline recommendation.
Information and communication strategy
The major focus of the revised recommendations is a comprehensive prevention campaign for all patients at risk for infective endocarditis (figure 1).
The information strategy includes the following key elements:
- Knowledge transfer to increase awareness for good dental and skin hygiene
- Education on symptoms consistent with infective endocarditis and the appropriate steps when these symptoms occur (i.e., get in contact with the doctor, obtain blood culture prior to administration of antibiotic therapy)
Considering that early diagnosis and appropriate treatment of infective endocarditis can be lifesaving, patient education is a central element of the prevention strategy. For this reason, the Swiss expert group, in collaboration with the Swiss Heart Foundation, has created a flyer illustrating the most important issues concerning infective endocarditis. This flyer is being distributed to all patients at risk for infective endocarditis, irrespective of their risk categorization (figure 1). The purpose of this flyer is for patient education and as a supportive instrument for care givers and providers in the field of heart diseases.
Patients with the highest risk for infective endocarditis require antibiotic prophylaxis prior to dental intervention. These patients only will also receive a separate antibiotic card. There are flyer and card versions for adults and for children (figure 1). For non-dental interventions, specific recommendations can be found on the corresponding websites (figure 2).
Additional patient information can be found on the following websites: www.endocarditis.ch [German] and www.endocardites.ch [French]. An educational movie will be available soon.
We are indebted to the Swiss Heart Foundation for their excellent collaboration and generous support regarding public information. We thank Prof. Dr. med. dent. Michael Bornstein, Department of Oral Health and Medicine, University Center for Dental Medicine Basel UZB, University of Basel, Basel, Switzerland, for his support with dental medicine aspects.
No financial support and no other potential conflicts of interest relevant to this article were reported.
Correspondence: Prof. Dr. med. P. Sendi, Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, CH-4031 Basel, parham.sendi[at]usb.ch, Institute for Infectious Diseases, University of Bern, CH-3010 Bern, parham.sendi[at]ifik.unibe.ch
1 Jaussi A, Flückiger U. Revidierte schweizerische Richtlinien für die Endokarditis-Prophylaxe. Kardiovaskuläre Medizin. 2008;11(12):392–400. doi:. http://dx.doi.org/10.4414/cvm.2008.01375
2 Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128. doi:. http://dx.doi.org/10.1093/eurheartj/ehv319 PubMed
3 Swissnoso. Nationales Zentrum für Infektionsprävention. Sample-Guideline: perioperative Antibiotikaprophylaxe. Available at: https://www.swissnoso.ch/fileadmin/module/ssi_intervention/Dokumente_D/4_Sample_Guidelines/180816_Sample-Guideline_AMP_de.pdf.
4 Schweizerische Gesellschaft für Gastroenterologie; Société Suisse de Gastroentérologie; Societa Svizzera di Gastroenterologia. Antibiotic Prophylaxis for Gastrointestinal Endoscopy. Available at: https://sggssg.ch/fileadmin/user_upload/Antibiotikaprophylaxe_in_der_Gastroenterologie_2018.pdf.
5 François M, Bingen EH, Lambert-Zechovsky NY, Mariani-Kurkdjian P, Nottet JB, Narcy P. Bacteremia during tonsillectomy. Arch Otolaryngol Head Neck Surg. 1992;118(11):1229–31. doi:. http://dx.doi.org/10.1001/archotol.1992.01880110097017 PubMed
6 Kaygusuz I, Gök U, Yalçin S, Keleş E, Kizirgil A, Demirbağ E. Bacteremia during tonsillectomy. Int J Pediatr Otorhinolaryngol. 2001;58(1):69–73. doi:. http://dx.doi.org/10.1016/S0165-5876(00)00471-7 PubMed
8 Klug TE, Henriksen JJ, Rusan M, Fuursted K, Ovesen T. Bacteremia during quinsy and elective tonsillectomy: an evaluation of antibiotic prophylaxis recommendations for patients undergoing tonsillectomy. J Cardiovasc Pharmacol Ther. 2012;17(3):298–302. doi:. http://dx.doi.org/10.1177/1074248411423023 PubMed
9 Milder EA, Rizzi MD, Morales KH, Ross RK, Lautenbach E, Gerber JS. Impact of a new practice guideline on antibiotic use with pediatric tonsillectomy. JAMA Otolaryngol Head Neck Surg. 2015;141(5):410–6. doi:. http://dx.doi.org/10.1001/jamaoto.2015.95 PubMed
10 Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–54. doi:. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.183095 PubMed
Published under the copyright license
“Attribution – Non-Commercial – NoDerivatives 4.0”.
No commercial reuse without permission.